Maximal-Effort Cytoreductive Surgery for Ovarian Cancer Patients with a High Tumor Burden: Variations in Practice and Impact on Outcome

被引:71
作者
Hall, Marcia [1 ]
Savvatis, Konstantinos [2 ,3 ]
Nixon, Katherine [4 ,5 ]
Kyrgiou, Maria [4 ,5 ]
Hariharan, Kuhan [1 ]
Padwick, Malcolm [6 ]
Owens, Owen [6 ]
Cunnea, Paula [4 ,5 ]
Campbell, Jeremy [7 ]
Farthing, Alan [4 ,5 ]
Stumpfle, Richard [7 ]
Vazquez, Ignacio [1 ]
Watson, Neale [8 ]
Krell, Jonathan [4 ,5 ]
Gabra, Hani [4 ,5 ,9 ]
Rustin, Gordon [1 ]
Fotopoulou, Christina [4 ,5 ,7 ]
机构
[1] Mt Vernon Canc Ctr, Northwood, Middx, England
[2] Barts Heart Ctr, Inherited Cardiovasc Dis Unit, London, England
[3] Queen Mary Univ, William Harvey Res Inst, London, England
[4] Imperial Coll London, Dept Surg & Canc, London, England
[5] Imperial Coll NHS Trust, West London Gynecol Canc Ctr, London, England
[6] WHH NHS Trust, West Hertfordshire Gynaecol Canc Ctr, Watford, England
[7] Hammersmith Hosp, Imperial Coll Healthcare NHS Trust, Ctr Perioperat Med & Crit Care Res, Dept Anaesthet, Ham House, London, England
[8] Hillingdon Hosp, Dept Gynaecol, Uxbridge, Middx, England
[9] AstraZeneca, IMED Biotech Unit, Early Clin Dev, Cambridge, England
关键词
COMPLEX SURGERY; SURVIVAL; ONCOLOGY; SOCIETY; WOMEN;
D O I
10.1245/s10434-019-07516-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background This study aimed to compare the outcomes of two distinct patient populations treated within two neighboring UK cancer centers (A and B) for advanced epithelial ovarian cancer (EOC). Methods A retrospective analysis of all new stages 3 and 4 EOC patients treated between January 2013 and December 2014 was performed. The Mayo Clinic surgical complexity score (SCS) was applied. Cox regression analysis identified the impact of treatment methods on survival. Results The study identified 249 patients (127 at center A and 122 in centre B) without significant differences in International Federation of Gynecology and Obstetrics (FIGO) stage (FIGO 4, 29.7% at centers A and B), Eastern Cooperative Oncology Group (ECOG) performance status (ECOG < 2, 89.9% at centers A and B), or histology (serous type in 84.1% at centers A and B). The patients at center A were more likely to undergo surgery (87% vs 59.8%; p < 0.001). The types of chemotherapy and the patients receiving palliative treatment alone were equivalent between the two centers (3.6%). The median SCS was significantly higher at center A (9 vs 2; p < 0.001) with greater tumor burden (9 vs 6 abdominal fields involved; p < 0.001), longer median operation times (285 vs 155 min; p < 0.001), and longer hospital stays (9 vs 6 days; p < 0.001), but surgical morbidity and mortality were equivalent. The independent predictors of reduced overall survival (OS) were non-serous histology (hazard ratio [HR], 1.6; 95% confidence interval [CI] 1.04-2.61), ECOG higher than 2 (HR, 1.9; 95% CI 1.15-3.13), and palliation alone (HR, 3.43; 95% CI 1.51-7.81). Cytoreduction, of any timing, had an independent protective impact on OS compared with chemotherapy alone (HR, 0.31 for interval surgery and 0.39 for primary surgery), even after adjustment for other prognostic factors. Conclusions Incorporating surgery into the initial EOC management, even for those patients with a greater tumor burden and more disseminated disease, may require more complex procedures and more resources in terms of theater time and hospital stay, but seems to be associated with a significant prolongation of the patients overall survival compared with chemotherapy alone.
引用
收藏
页码:2943 / 2951
页数:9
相关论文
共 25 条
[1]   Aggressive surgical effort and improved survival in advanced-stage ovarian cancer [J].
Aletti, GD ;
Dowdy, SC ;
Gostout, BS ;
Jones, MB ;
Stanhope, CR ;
Wilson, TO ;
Podratz, KC ;
Cliby, WA .
OBSTETRICS AND GYNECOLOGY, 2006, 107 (01) :77-85
[2]   Quality Improvement in the Surgical Approach to Advanced Ovarian Cancer: The Mayo Clinic Experience [J].
Aletti, Giovanni D. ;
Dowdy, Sean C. ;
Gostout, Bobbie S. ;
Jones, Monica B. ;
Stanhope, Robert C. ;
Wilson, Timothy O. ;
Podratz, Karl C. ;
Cliby, William A. .
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2009, 208 (04) :614-620
[3]   Aggressive and complex surgery for advanced ovarian cancer: An economic analysis [J].
Aletti, Giovanni D. ;
Podratz, Karl C. ;
Moriarty, James R. ;
Cliby, William A. ;
Long, Kirsten Hall .
GYNECOLOGIC ONCOLOGY, 2009, 112 (01) :16-21
[4]  
[Anonymous], 2018, BMJ BRIT MED J, DOI DOI 10.1136/BMJ.K4001
[5]   Surgical readmission and survival in women with ovarian cancer: Are short-term quality metrics incentivizing decreased long-term survival? [J].
Barber, Emma L. ;
Rossi, Emma C. ;
Gehrig, Paola A. .
GYNECOLOGIC ONCOLOGY, 2017, 147 (03) :607-611
[6]   Factors Affecting Short-term Mortality in Women With Ovarian, Tubal, or Primary Peritoneal Cancer Population-Based Cohort Analysis of English National Cancer Registration Data [J].
Barclay, Matthew ;
Gildea, Carolynn ;
Poole, Jason ;
Hirschowitz, Lynn ;
Menon, Usha ;
Nordin, Andrew .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 (01) :56-65
[7]   Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis [J].
Bristow, RE ;
Tomacruz, RS ;
Armstrong, DK ;
Trimble, EL ;
Montz, FJ .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (05) :1248-1259
[8]   European Surgical Education and Training in Gynecologic Oncology: The impact of an Accredited Fellowship [J].
Chiva, Luis M. ;
Minguez, Jose ;
Querleu, Denis ;
Cibula, David ;
du Bois, Andreas .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 (04) :819-825
[9]  
Clamp AR, 2017, EUR SOC MED ONC 2017
[10]   Thirty-day unplanned hospital readmission in ovarian cancer patients undergoing primary or interval cytoreductive surgery: systematic literature review [J].
Clark, Rachel M. ;
Rice, Laurel W. ;
del Carmen, Marcela G. .
GYNECOLOGIC ONCOLOGY, 2018, 150 (02) :370-377